Boris Peaker
Stock Analyst at Jones Trading
(2.21)
# 2,675
Out of 5,182 analysts
19
Total ratings
40%
Success rate
12.7%
Average return
Main Sectors:
Stocks Rated by Boris Peaker
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLAY Relay Therapeutics | Initiates: Hold | $18 | $13.20 | +36.36% | 1 | Apr 14, 2026 | |
| MGNX MacroGenics | Downgrades: Hold | n/a | $3.01 | - | 3 | May 10, 2024 | |
| LNTH Lantheus Holdings | Initiates: Outperform | $100 | $82.76 | +20.83% | 1 | Dec 4, 2023 | |
| ADCT ADC Therapeutics | Downgrades: Market Perform | n/a | $3.78 | - | 1 | Nov 9, 2023 | |
| PCRX Pacira BioSciences | Upgrades: Outperform | $50 | $25.44 | +96.54% | 1 | Aug 3, 2023 | |
| PCVX Vaxcyte | Initiates: Outperform | n/a | $58.97 | - | 1 | Apr 18, 2023 | |
| XNCR Xencor | Initiates: Outperform | n/a | $12.08 | - | 1 | Dec 6, 2022 | |
| EBS Emergent BioSolutions | Maintains: Market Perform | $30 → $29 | $8.14 | +256.27% | 1 | Sep 12, 2022 | |
| CTMX CytomX Therapeutics | Downgrades: Market Perform | n/a | $4.17 | - | 2 | Jul 11, 2022 | |
| NKTR Nektar Therapeutics | Downgrades: Market Perform | n/a | $84.24 | - | 1 | Mar 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.15 | - | 1 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $120.56 | - | 1 | Jul 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $769.19 | - | 1 | Jun 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $95 → $102 | $110.53 | -7.72% | 1 | Jun 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.25 | - | 1 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $35.76 | - | 1 | Oct 22, 2018 |
Relay Therapeutics
Apr 14, 2026
Initiates: Hold
Price Target: $18
Current: $13.20
Upside: +36.36%
MacroGenics
May 10, 2024
Downgrades: Hold
Price Target: n/a
Current: $3.01
Upside: -
Lantheus Holdings
Dec 4, 2023
Initiates: Outperform
Price Target: $100
Current: $82.76
Upside: +20.83%
ADC Therapeutics
Nov 9, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $3.78
Upside: -
Pacira BioSciences
Aug 3, 2023
Upgrades: Outperform
Price Target: $50
Current: $25.44
Upside: +96.54%
Vaxcyte
Apr 18, 2023
Initiates: Outperform
Price Target: n/a
Current: $58.97
Upside: -
Xencor
Dec 6, 2022
Initiates: Outperform
Price Target: n/a
Current: $12.08
Upside: -
Emergent BioSolutions
Sep 12, 2022
Maintains: Market Perform
Price Target: $30 → $29
Current: $8.14
Upside: +256.27%
CytomX Therapeutics
Jul 11, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $4.17
Upside: -
Nektar Therapeutics
Mar 15, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $84.24
Upside: -
Mar 3, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $2.15
Upside: -
Jul 29, 2021
Initiates: Outperform
Price Target: n/a
Current: $120.56
Upside: -
Jun 12, 2017
Initiates: Outperform
Price Target: n/a
Current: $769.19
Upside: -
Jun 27, 2022
Maintains: Market Perform
Price Target: $95 → $102
Current: $110.53
Upside: -7.72%
Aug 13, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.25
Upside: -
Oct 22, 2018
Initiates: Outperform
Price Target: n/a
Current: $35.76
Upside: -